Form 4: MapLight CSO Sells Shares for Tax Obligations

Chief Scientific Officer James Woodruff sold 4,513 shares of MapLight Therapeutics to cover statutory tax withholding obligations.

Summary

• James Woodruff, Chief Scientific Officer of MapLight Therapeutics, Inc., executed sales of 4,513 shares of Voting Common Stock.
• The transactions occurred on April 15 and April 16, 2026.
• The sales were conducted to satisfy statutory tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, the reporting person retains beneficial ownership of 295,157 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative to satisfy tax obligations rather than a discretionary divestment.

Positives

• The sale was non-discretionary, specifically executed to cover tax liabilities associated with equity vesting, indicating continued long-term alignment with the company.

Negatives

• Reduction in the direct equity stake held by a key executive.

Risks

• Market volatility affecting the weighted average price of shares sold for tax coverage.

Future Outlook

No forward-looking guidance or strategic outlook provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that insider sales for tax withholding are standard corporate practice and generally do not signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction follows standard SEC compliance protocols for executive equity compensation.
• The use of weighted average pricing for tax-related sales is consistent with industry-standard reporting practices for biotechnology firms.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was limited to tax-related equity liquidation.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

MapLight Therapeutics, MPLT, Insider Trading, Form 4, Chief Scientific Officer, Equity Vesting